Key Developments: Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,890.00INR
3:47am EDT
Change (% chg)

Rs-45.55 (-2.35%)
Prev Close
Rs1,935.55
Open
Rs1,910.00
Day's High
Rs1,924.95
Day's Low
Rs1,873.60
Volume
608,789
Avg. Vol
1,220,624
52-wk High
Rs2,115.00
52-wk Low
Rs1,280.20

Search Stocks

Latest Key Developments (Source: Significant Developments)

Lupin Ltd receives FDA approval for Generic Prilosec Capsules
Thursday, 27 Aug 2015 06:15am EDT 

Lupin Ltd:Has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the USFDA to market a generic version of AstraZeneca Pharmaceuticals LP Prilosec Delayed-Release capsules 40 mg.  Full Article

Lupin Ltd receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg
Thursday, 20 Aug 2015 07:42am EDT 

Lupin Ltd:Receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg.  Full Article

Lupin Ltd announces New Center of Excellence for Inhalation Research in Florida
Friday, 7 Aug 2015 07:43am EDT 

Lupin Ltd:Announces opening of its new center of excellence for Inhalation Research in Coral Springs, Florida.  Full Article

Lupin Ltd announces acquires specialty product portfolio in Germany
Friday, 24 Jul 2015 08:11am EDT 

Lupin Ltd:Has entered into a strategic asset purchase agreement with Temmler Pharma Gmbh & Co. KG a part of the Aenova Group, to acquire Temmler's specialty product portfolio subject to certain closing conditions.  Full Article

Lupin Ltd acquires GAVIS to Expand US Generic Business
Thursday, 23 Jul 2015 05:30am EDT 

Lupin Ltd:Says has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS), subject to certain closing conditions, in a transaction valued at $ 880 mln, cash free and debt free.  Full Article

Brazil Suspends Drug Ingredient Import From Lupin Ltd - Business Standard
Tuesday, 7 Jul 2015 08:00pm EDT 

Lupin Ltd:Says import suspension of its drug ingredient by the Brazilian drug regulator - Business Standard.Says expects to resume supply by September from another plant with which the regulator had no concerns.Says Brazilian drug regulator said in a statement that it has suspended imports of all beta-lactam cephalosporin pharmaceutical ingredients and all imported drugs using these inputs.Says regulator added that the analysis considered unsatisfactory inputs.Says irregularities were detected during the inspection for verification of good manufacturing practices.  Full Article

IPAB sets aside order passed against Lupin Ltd - Business Standard
Monday, 6 Jul 2015 08:00pm EDT 

Lupin Ltd:Says Intellectual Property Appellate Board (IPAB) has set aside an order of the Assistant Controller of Patents and Designs, Mumbai, which refused patent for Lupin for its chewable antibiotic drug Cefixime - Business Standard.  Full Article

Lupin Ltd acquires Biocom in Russia
Thursday, 2 Jul 2015 10:13am EDT 

Lupin Ltd:Says acquisition of 100% equity stake in ZAO Biocom in Russia subject to certain closing conditions.  Full Article

Lupin Ltd to raise funds up to 75 bln Indian Rupees-Business Standard
Tuesday, 23 Jun 2015 01:27am EDT 

Lupin Ltd:Says the Board have given in-principle approval for raising funds of up to 75.00 bln Indian Rupees-Business Standard.Raising of funds is through issue of securities that is equity shares, GDRs, ADRs, convertible bonds, equity linked instruments etc.  Full Article

Lupin Ltd acquires Medquimica in Brazil
Thursday, 14 May 2015 02:13am EDT 

Lupin Ltd:Says acquisition of 100 pct equity stake in Medquimica Industria Farmaceutica S.A, Brazil subject to certain closing conditions.Acquisition makes Lupin 's foray into the high growth Brazilian market and would also shore up its position in Latin American Pharmaceuticals market given the company's acquisition of Laboratorios Grin in Mexico last fiscal.  Full Article

Akorn Inc's Hi-Tech Pharmacal infringes Allergan glaucoma drug patents

NEW YORK - An Akorn Inc unit's proposed generic glaucoma drug infringed three Allergan Inc patents on its Lumigan topical treatment for the eye disease, a U.S. appeals court ruled on Tuesday.

Search Stocks